GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chromocell Therapeutics Corp (AMEX:CHRO) » Definitions » EBITDA Margin %

Chromocell Therapeutics (Chromocell Therapeutics) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Chromocell Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Chromocell Therapeutics's EBITDA for the three months ended in Mar. 2024 was $-1.93 Mil. Chromocell Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Chromocell Therapeutics's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Chromocell Therapeutics EBITDA Margin % Historical Data

The historical data trend for Chromocell Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chromocell Therapeutics EBITDA Margin % Chart

Chromocell Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
-329.50 - - -

Chromocell Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chromocell Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Chromocell Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chromocell Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chromocell Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Chromocell Therapeutics's EBITDA Margin % falls into.



Chromocell Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Chromocell Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-6.862/0
= %

Chromocell Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-1.934/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chromocell Therapeutics  (AMEX:CHRO) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Chromocell Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Chromocell Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chromocell Therapeutics (Chromocell Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Chromocell Therapeutics Corp is a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Its clinical focus is to selectively target the sodium ion-channel known as "NaV1.7", as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology.

Chromocell Therapeutics (Chromocell Therapeutics) Headlines